ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors).

@article{RedelmanSidi2018ESCMIDSG,
  title={ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors).},
  author={Gil Redelman-Sidi and Oliver Michielin and Carlos Cervera and Camillo Ribi and Jos{\'e} Mar{\'i}a Aguado and Mario Fern{\'a}ndez-Ruiz and Oriol Manuel},
  journal={Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases},
  year={2018},
  volume={24 Suppl 2},
  pages={
          S95-S107
        }
}
  • Gil Redelman-Sidi, Oliver Michielin, +4 authors Oriol Manuel
  • Published in
    Clinical microbiology and…
    2018
  • Medicine, Biology
  • BACKGROUND The present review is part of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies. AIMS To review, from an infectious diseases perspective, the safety profile of immune checkpoint inhibitors, LFA-3-targeted agents, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors, and to suggest… CONTINUE READING

    Create an AI-powered research feed to stay up to date with new papers like this posted to ArXiv

    11
    Twitter Mentions

    Citations

    Publications citing this paper.
    SHOWING 1-10 OF 12 CITATIONS

    Progressive Multifocal Leukoencephalopathy after Treatment with Nivolumab

    VIEW 4 EXCERPTS
    CITES BACKGROUND
    HIGHLY INFLUENCED

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 121 REFERENCES

    [Infections and fingolimod].

    VIEW 6 EXCERPTS

    Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older.

    VIEW 7 EXCERPTS
    HIGHLY INFLUENTIAL

    The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma.

    VIEW 3 EXCERPTS

    Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults.

    VIEW 7 EXCERPTS
    HIGHLY INFLUENTIAL